NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced today that it will amend and restate its financial statements for the quarter ended March 31, 2026, after identifying a revenue recognition error during a post-release review. The restatement, which corrects a one-time revenue overstatement of approximately $0.5 million, does not affect the company's full-year revenue guidance, cash position, or ongoing business operations.
The error was attributed to a customer order modification on product shipment at the end of the quarter. According to the company, the restatement reduces initially reported revenue of $2.4 million by about $0.5 million, resulting in a gross profit overstatement of $0.3 million and an understatement of operating loss and net loss by approximately $0.3 million. No prior periods were impacted, and the company stated that its product revenue guidance for fiscal year 2026 remains unchanged at at least $10.5 million.
Dave Rosa, CEO of NeuroOne, emphasized that this is a one-time correction. “This one-time correction does not change our revenue projections for the year,” Rosa said. “Our operations remain strong, our growth strategy is unchanged, and we continue to anticipate product revenue for fiscal 2026 of at least $10.5 million.”
The company's Audit Committee, after discussions with management, determined on May 21 that the financial statements in the Quarterly Report on Form 10-Q filed on May 12 should no longer be relied upon. NeuroOne intends to file an amendment to the Form 10-Q in the coming weeks. The company has also initiated measures to improve its internal controls over financial reporting to prevent similar issues.
This restatement comes at a time when NeuroOne is focused on commercializing its minimally invasive electrode technology platform. The company markets four FDA-cleared product families, including the Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System for the brain, and OneRF Trigeminal Nerve Ablation System. These technologies aim to reduce hospitalizations and surgical procedures while improving outcomes for patients with neurological disorders. Additionally, NeuroOne is engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs.
For investors and the medical technology industry, the restatement highlights the importance of rigorous revenue recognition processes, especially with customer order modifications at quarter-end. However, the company's reaffirmation of its full-year guidance may signal that the underlying business remains on track. NeuroOne's cash position as of March 31, 2026, was not affected by the restatement, and the company continues to pursue its growth plans.
The company's forward-looking statements, including its 2026 revenue guidance and growth strategies, are subject to risks and uncertainties, as detailed in its filings with the Securities and Exchange Commission. For more information about NeuroOne and its technology, visit nmtc1.com.
